MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis Corrigendum in /10.3892/etm.2022.11390

Hu,Liang-Kai; Chen,Jian-Qing; Zheng,Hao; Tao,Yuan-Ping; Yang,Yuan; Xu,Xuan-Fu

doi:10.3892/etm.2021.10865

MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis

Corrigendum in: /10.3892/etm.2022.11390

Authors:
- Liang-Kai Hu
- Jian-Qing Chen
- Hao Zheng
- Yuan-Ping Tao
- Yuan Yang
- Xuan-Fu Xu
View Affiliations

Affiliations: Department of Gastroenterology, Shidong Hospital, Shanghai 200438, P.R. China, Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China
Published online on: October 11, 2021 https://doi.org/10.3892/etm.2021.10865
Article Number: 1430
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a complex type of liver disease that represents an important global health threat. The mechanistic basis of this disease remains incompletely understood. The present study sought to explore whether microRNA (miR)-506-3p served a functional role in the onset and/or progression of NAFLD. To that end, high levels of glucose were used to treat liver cancer cell lines (HepG2 and Huh7) to model hepatic steatosis, and the expression levels of miR-506-3p and its downstream target genes were assessed. The cells of this hepatic steatosis model were transfected with miR-506-3p mimic molecules to explore the effect of miR-506-3p overexpression on cell viability, target gene expression and AMP-activated protein kinase (AMPK) phosphorylation. Via bioinformatics approaches, sirtuin 1 (SIRT1) was identified as a potential miR-506-3p target gene with relevance in NAFLD, and this interaction was confirmed via luciferase reporter assay. In the hepatic steatosis model of the present study, miR-506-3p expression level was significantly increased, whereas SIRT1 mRNA/protein levels and AMPK phosphorylation levels were markedly decreased. Transfection of the cells with miR-506-3p mimics led to significant SIRT1 downregulation, while miR-506-3p inhibitor molecules exhibited the opposite effect, with similar trends observed in the phosphorylation status of AMPK. These results suggested that miR-506-3p can inhibit SIRT1 expression and associated AMPK phosphorylation in HepG2 and Huh7 cells in an in vitro hepatic steatosis model system. These data indicated that the miR-506-3p/SIRT1/AMPK axis may be valuable as a therapeutic target in patients affected by NAFLD.

View Figures

View References

1	Gui Y, Pan Q, Chen X, Xu S, Luo X and Chen L: The association between obesity related adipokines and risk of breast cancer: A meta-analysis. Oncotarget. 8:75389–75399. 2017.PubMed/NCBI View Article : Google Scholar
2	Benedict M and Zhang X: Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 9:715–732. 2017.PubMed/NCBI View Article : Google Scholar
3	Nassir F and Ibdah JA: Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 22:10084–10092. 2016.PubMed/NCBI View Article : Google Scholar
4	Tobita T, Guzman-Lepe J, Takeishi K, Nakao T, Wang Y, Meng F, Deng CX, Collin de l'Hortet A and Soto-Gutierrez A: SIRT1 disruption in human fetal hepatocytes leads to increased accumulation of glucose and lipids. PLoS One. 11(e0149344)2016.PubMed/NCBI View Article : Google Scholar
5	Arab Sadeghabadi Z, Nourbakhsh M, Pasalar P, Emamgholipour S, Golestani A, Larijani B and Razzaghy-Azar M: Reduced gene expression of sirtuins and active AMPK levels in children and adolescents with obesity and insulin resistance. Obes Res Clin Pract. 12:167–173. 2018.PubMed/NCBI View Article : Google Scholar
6	Kitada M and Koya D: SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J. 37:315–325. 2013.PubMed/NCBI View Article : Google Scholar
7	Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 144:5179–5183. 2003.PubMed/NCBI View Article : Google Scholar
8	Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, et al: SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. 283:20015–20026. 2008.PubMed/NCBI View Article : Google Scholar
9	Jinek M and Doudna JA: A three-dimensional view of the molecular machinery of RNA interference. Nature. 457:405–412. 2009.PubMed/NCBI View Article : Google Scholar
10	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI View Article : Google Scholar
11	Rottiers V and Näär AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 13:239–250. 2012.PubMed/NCBI View Article : Google Scholar
12	Ceccarelli S, Panera N, Gnani D and Nobili V: Dual role of microRNAs in NAFLD. Int J Mol Sci. 14:8437–8455. 2013.PubMed/NCBI View Article : Google Scholar
13	Kerr TA, Korenblat KM and Davidson NO: MicroRNAs and liver disease. Transl Res. 157:241–252. 2011.PubMed/NCBI View Article : Google Scholar
14	Lakner AM, Bonkovsky HL and Schrum LW: microRNAs: Fad or future of liver disease. World J Gastroenterol. 17:2536–2542. 2011.PubMed/NCBI View Article : Google Scholar
15	Hu CY, You P, Zhang J, Zhang H and Jiang N: MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4. Eur Rev Med Pharmacol Sci. 23:5133–5138. 2019.PubMed/NCBI View Article : Google Scholar
16	Deng Q, Xie L and Li H: MiR-506 suppresses cell proliferation and tumor growth by targeting Rho-associated protein kinase 1 in hepatocellular carcinoma. Biochem Biophys Res Commun. 467:921–927. 2015.PubMed/NCBI View Article : Google Scholar
17	Wang Z, Si M, Yang N, Zhang H, Fu Y, Yan K, Zong Y, Zhu N and Wei Y: MicroRNA-506 suppresses invasiveness and metastasis of human hepatocellular carcinoma cells by targeting IL8. Am J Cancer Res. 8:1586–1594. 2018.PubMed/NCBI
18	Debes JD, Boonstra A and de Knegt RJ: NAFLD-related hepatocellular carcinoma and the four horsemen of the apocalypse. Hepatology. 71:774–776. 2020.PubMed/NCBI View Article : Google Scholar
19	Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A and Flowers CR: 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 66:443–459. 2016.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Lin MJ, Dai W, Scott MJ, Li R, Zhang YQ, Yang Y, Chen LZ and Huang XS: Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway. Oncotarget. 8:108802–108809. 2017.PubMed/NCBI View Article : Google Scholar
22	da Silva-Santi LG, Antunes MM, Caparroz-Assef SM, Carbonera F, Masi LN, Curi R, Visentainer JV and Bazotte RB: Liver fatty acid composition and inflammation in mice fed with high-carbohydrate diet or high-fat diet. Nutrients. 8(8)2016.PubMed/NCBI View Article : Google Scholar
23	Santamarina AB, Oliveira JL, Silva FP, Carnier J, Mennitti LV, Santana AA, de Souza GH, Ribeiro EB, Oller do Nascimento CM, Lira FS, et al: Green tea extract rich in epigallocatechin-3-gallate prevents fatty liver by AMPK activation via LKB1 in mice fed a high-fat diet. PLoS One. 10(e0141227)2015.PubMed/NCBI View Article : Google Scholar
24	Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P and Auwerx J: AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. Nature. 458:1056–1060. 2009.PubMed/NCBI View Article : Google Scholar
25	Lan F, Cacicedo JM, Ruderman N and Ido Y: SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 283:27628–27635. 2008.PubMed/NCBI View Article : Google Scholar
26	Kitade H, Chen G, Ni Y and Ota T: Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 9(9)2017.PubMed/NCBI View Article : Google Scholar
27	Cao Y, Jiang X, Ma H, Wang Y, Xue P and Liu Y: SIRT1 and insulin resistance. J Diabetes Complications. 30:178–183. 2016.PubMed/NCBI View Article : Google Scholar
28	Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X and Li X: Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:327–338. 2009.PubMed/NCBI View Article : Google Scholar
29	Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 25:666–681. 2014.PubMed/NCBI View Article : Google Scholar
30	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
31	Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H and Rodrigues CM: miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 58:119–125. 2013.PubMed/NCBI View Article : Google Scholar
32	Colak Y, Yesil A, Mutlu HH, Caklili OT, Ulasoglu C, Senates E, Takir M, Kostek O, Yilmaz Y, Yilmaz Enc F, et al: A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J Gastrointestin Liver Dis. 23:311–319. 2014.PubMed/NCBI View Article : Google Scholar
33	Wang LF, Wang XN, Huang CC, Hu L, Xiao YF, Guan XH, Qian YS, Deng KY and Xin HB: Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway. Lipids Health Dis. 16(82)2017.PubMed/NCBI View Article : Google Scholar
34	Sun L, Wang Y, Song Y, Cheng XR, Xia S, Rahman MR, Shi Y and Le G: Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice. Biochem Biophys Res Commun. 458:86–91. 2015.PubMed/NCBI View Article : Google Scholar
35	Ao R, Wang Y, Tong J and Wang BF: Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1. Med Sci Monit. 22:3804–3819. 2016.PubMed/NCBI View Article : Google Scholar
36	Kim HJ, Joe Y, Yu JK, Chen Y, Jeong SO, Mani N, Cho GJ, Pae HO, Ryter SW and Chung HT: Carbon monoxide protects against hepatic ischemia/reperfusion injury by modulating the miR-34a/SIRT1 pathway. Biochim Biophys Acta. 1852:1550–1559. 2015.PubMed/NCBI View Article : Google Scholar
37	Boudaba N, Marion A, Huet C, Pierre R, Viollet B and Foretz M: AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development. EBioMedicine. 28:194–209. 2018.PubMed/NCBI View Article : Google Scholar